Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to ...
Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.
We recently published an article titled Why These 10 Dividend Stocks Are Declining? In this article, we are going to take a ...
Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...
This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results